Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares IssuedShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cue Biopharma (CUE) Gains from Sales and Divestitures (2019 - 2022)

Cue Biopharma (CUE) has disclosed Gains from Sales and Divestitures for 4 consecutive years, with $98335.0 as the latest value for Q4 2022.

  • Quarterly Gains from Sales and Divestitures fell 25.32% to $98335.0 in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $98335.0 through Dec 2022, down 25.32% year-over-year, with the annual reading at $98335.0 for FY2022, 25.32% down from the prior year.
  • Gains from Sales and Divestitures hit $98335.0 in Q4 2022 for Cue Biopharma, roughly flat from $98335.0 in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $131667.0 in Q4 2021 to a low of $16666.0 in Q1 2020.
  • Historically, Gains from Sales and Divestitures has averaged $64444.5 across 4 years, with a median of $74166.5 in 2020.
  • Biggest YoY gain for Gains from Sales and Divestitures was 450.03% in 2022; the steepest drop was 25.32% in 2022.
  • Year by year, Gains from Sales and Divestitures stood at $33333.0 in 2019, then skyrocketed by 70.0% to $56665.0 in 2020, then soared by 132.36% to $131667.0 in 2021, then dropped by 25.32% to $98335.0 in 2022.
  • Business Quant data shows Gains from Sales and Divestitures for CUE at $98335.0 in Q4 2022, $98335.0 in Q3 2022, and $91668.0 in Q2 2022.